Despite careful monitoring of oral anticoagulant treatment (OAT), some international normalized ratio (INR) for prothrombin time values will fall outside the therapeutic range. Considerable changes in serial INR results from OAT patients may be caused by random fluctuation alone, and, for statistical reasons, a fraction of the INR values will fall outside therapeutic range and interfere with dose adjustments. On the basis of therapeutic intervals and statistical evaluation of reference changes, we suggest and discuss an alternative method for interpretation of serial INR measurements. Retrospective evaluation of senal measurements of INR from OAT patients revealed an "overshooting" phenomenon. When a dose was adjusted on the basis of insignificant change in INR value, the subsequent INR value generally fell in the opposite direction. If a further change of dose was initiated because of the new INR value, a similar course in the opposite direction was observed. This "pingpong" effect renders patients in a fluctuating state of anticoagulation and may introduce increased risk of complications. The suggested method provides an objective criterion for dose adjustments in OAT, which should reduce patients' risk.
Indexing Terms: statistics/therapeutic drug monitoring/therapeutic interval/coumarin derivatives
Oral anticoagulant treatment (OAT) with coumarin derivatives has a well-established efficacy in prophylaxis and treatment of various thromboembolic disorders (1 ) 5 Although the pharmacological aspects of anticoagulation are reasonably well-described in general, the monitoring and management of OAT is still a complex task. Patients' responses during OAT are highly individual, and the average dose required for the maintenance of a therapeutic effect differs widely from patient to patient.
For the individual patient this variation may cause problems in terms of erroneous dose adjustment.
The efficacy and safety of OAT is directly related to the ability of avoiding thromboembolic and hemorrhagic complications (1) . The risk is closely related to the intensity of OAT and correlates (3) . During pharmacological therapy the measured results are interpreted in relation to the therapeutic interval, which reflects considerations with regard to optimal pharmacological effect, toxicology, and minimal number of side effects (1) . This is in contrast to biochemical analytes, which quires knowledge about the magnitude of the total variation (i.e., within-subject variation as well as the analytical and preanalytical variations) in healthy subjects or in patients under well-defined conditions. The change in a biochemical variable must exceed the total standard deviation multiplied by the z-value (a constant dependent on the chosen probability) to be considered significant.
The concept of critical difference (CD) or reference change incorporates these considerations (8, 9) . Since the dose response in OAT patients is easily impaired, just a small variation in diet, health status, compliance, or medication can introduce a large change in the extent of coagulation. In contrast, healthy individuals have a homeostatic intensity of anticoagulation on the very flat part of the theoretical dose-response curve, such that even large changes in the abovementioned extraneous factors will hardly be recognized in the coagulation response. In conclusion, the mean within-subject biological CV of INR measurements obtained from healthy volunteers is expected to be smaller than that for OAT patients (10) (11) (12) and not relevant for OAT. For OAT the concept of total variation of INR values needs to be redefined as total variation during steady-state conditions of treatment, and is referred to here as total in-treatment variation. Furthermore, the estimates of within-subject variation from patients in OAT do not describe a "true" biological variation. In the following, we will use the term "intreatment within-subject variation"
Within-Subject Variation of INR in OAT Patients
(S1 treatment or CVin treatment) of estimates of variations obtained from patients in OAT treatment.
In-treatment within-subject variation can be considered the within-subject variation combined with a pharmacologically determined variation (Appendix 1). (8, 9) .
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In clinical management of OAT, the clinician has to rely on INR values when assessing the intensity of anticoagulation.
Before changing the dose of vitamin K antagonist, the present INR value must be interpreted in relation to the therapeutic interval and to the former against the INR, in a difference plot. This reveals the change in INR, whether it is in a positive or negative direction (13) . Applying the therapeutic interval in the plot further reveals whether the latest measured INR is within or outside the therapeutic interval (Fig. 1A) . If the measured INR is within the therapeutic interval, one must consider whether this indicates steady-state intensity of anticoagulation, or drifting or unstable OAT. To evaluate whether the present INR result is due to expected random variability or to a significant change in INR, we must also know the total variation of INR (including in-treatment within-subject variation) for the individual. We earlier estimated the mean total in-treatment variation for patients on constant dose of coumarin derivative to be 10.1% (4, 10) . At the therapeutic target INR = 2.5, the CD is 0.7 INR (Eq. 2). At target INR = 3.5, the CD is 1.0 INR, at a 5% level of significance, corresponding to a 95% range for differences (4) . Given assumptions of linearity between the corresponding CDs for different therapeutic targets, decision limits for the CD can be illustrated graphically with sloping lines connecting the points, which equals the CDs for the different INIR values. INR is defmed only for PT obtained from patients on OAT, but since the CVin treatment is assumed constant (10%), the lines defining the CD will theoretically pass through zero (Fig. 1B) . levels of certainty for CD, different levels of probability of significance of change can be shown in the model (Fig. 1C) .
Results from a patient in steady-state and with CV10 treatment <10% are expected to be distributed within the therapeutic interval and the CD. However, results from a patient in steady-state (as well) but with a higher CV10treatment (e.g., 15%) will exceed the limit very often, which may result in frequent up-and downregulation of therapy (ping-pong effect). Dose adjustment in this situation might result in overshooting. Again, one must await the steady-state condition. However, if the INR value is high, indicating an unacceptable increase in the risk for side effects, reduction of dose must be considered solely on the basis of clinical judgment.
Retrospectively Evaluated Clinical Examples
Ping-Pong Effect
The average dose of coumarin derivative required for the maintenance of a therapeutic effect differs widely from patient to patient. of all similar persons, seems, in this situation, to be a better solution than just comparing mean variance from the population studied (14) .
Components of Within-Patient Variability
The biological component of variation (CVb) might be specific for the individual patient, whereas the pharmacological component may be determined The random variation on serially measured variables from pharmacologically treated patients must be assumed to be larger than for healthy individuals. When
Lin treatment
differs considerably from r of healthy individuals, as for INR from patients on OAT, then CVb may vary according to concentration.
It may, however, be impossible experimentally to separate biological from pharmacological variation, but also under these conditions, the assumption will probably be valid.
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